臨床薬理の進歩 No.41
45/216

文   献7)Wemhöner K, Friedrich C, Stallmeyer B, Coffey AJ, Grace A, Zumhagen S, et al. Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2) cause non-syndromic long-QT but not Timothy syndrome. J Mol Cell Cardiol 2015; 80: 186-95. 1)Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120: 1761-7. 2)Mizusawa Y, Horie M, Wilde, AA. Genetic and Clinical Advances in Congenital Long QT Syndrome. Cir J 2014; 78: 2827-33.3)Giudicessi JR, Ackerman MJ. Genotype-and phenotype-guided management of congenital long QT syndrome. Curr Probl Cardiol 2013; 38: 417-55. 4)Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 19-31.5)Boczek NJ, Best JM, Tester DJ, Giudicessi JR, Middha S, Evans JM, et al. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome. Circ Cardiovasc Genet 2013; 6: 279-89. 6)Fukuyama M, Wang Q, Kato K, Ohno S, Ding WG, Toyoda F, et al. Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation and variant phenotypes. Europace 2014; 16: 1828-37. 8)Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 2013; 31: 458-66.iPS細胞モデルを用いたQT延長症候群に対する新規Ca2+チャネル抑制メカニズムによる治療法開発9)Kiyonaka S, Wakamori M, Miki T, Uriu Y, Nonaka M, Bito H, et al. RIM1 confers sustained activity and neurotransmitter vesicle anchoring to presynaptic Ca2+ channels. Nat Neurosci 2007; 10: 691-701.10)Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008; 453: 524-8.11)Sasaki K, Makiyama T, Yoshida Y, Wuriyanghai Y, Kamakura T, Nishiuchi S, et al. Patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates S107 as a potential therapeutic agent for catecholaminergic polymorphic ventricular tachycardia. PLoS One 2016; 11: e0164795.12)Yamamoto Y, Makiyama T, Harita T, Sasaki K, Wuriyanghai Y, Hayano M, et al. Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation. Hum Mol Genet 2017; 26: 1670-7. 13)Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-4. 14)Woodruff ML, Lem J, Fain GL. Early receptor current of wild-type and transducin knockout mice: photosensitivity and light-induced Ca2+ release. J Physiol 2004; 557: 821-8.15)Stern JH, Kaupp UB, MacLeish PR. Control of the light-regulated current in rod photoreceptors by cyclic GMP, calcium, and l-cis-diltiazem. Proc Natl Acad Sci U S A 1986; 83: 1163-7.31

元のページ  ../index.html#45

このブックを見る